These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension. Halank M; Kolditz M; Opitz C; Hoeffken G; Ewert R Wien Klin Wochenschr; 2006 Feb; 118(1-2):54-9. PubMed ID: 16489527 [TBL] [Abstract][Full Text] [Related]
30. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Suntharalingam J; Hughes RJ; Goldsmith K; Doughty N; George P; Toshner M; Sheares KK; Pepke-Zaba J Vascul Pharmacol; 2007 Jun; 46(6):449-55. PubMed ID: 17368113 [TBL] [Abstract][Full Text] [Related]
31. Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model. Ried M; Potzger T; Neu R; Sziklavari Z; Szöke T; Liebold A; Hofmann HS; Hoenicka M Cardiovasc Drugs Ther; 2014 Feb; 28(1):45-51. PubMed ID: 24193244 [TBL] [Abstract][Full Text] [Related]
33. Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. Rosengarten B; Schermuly RT; Voswinckel R; Kohstall MG; Olschewski H; Weissmann N; Seeger W; Kaps M; Grimminger F; Ghofrani HA Cerebrovasc Dis; 2006; 21(3):194-200. PubMed ID: 16388195 [TBL] [Abstract][Full Text] [Related]
34. [Preliminary study on the efficacy and safety of oral sildenafil in pulmonary arterial hypertension in China]. Xiong CM; He JG; Lu XL; Shan GL; Wu BX; Zhu XY; Wu GH; Zeng XF; Guo T; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Tian HY; Li WM; Zhang DZ; Zhang C; Li MT; Liu HM; Guo YJ; Shen JY; Zhang WJ; Liu S; Zhou DX; Bao CD; Huang SA; Chen JY; Wu WF; Huang K; Li CL; Wang LH; He B Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(6):370-4. PubMed ID: 21418907 [TBL] [Abstract][Full Text] [Related]
35. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Bhatia S; Frantz RP; Severson CJ; Durst LA; McGoon MD Mayo Clin Proc; 2003 Oct; 78(10):1207-13. PubMed ID: 14531479 [TBL] [Abstract][Full Text] [Related]
36. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Zhang ZN; Jiang X; Zhang R; Li XL; Wu BX; Zhao QH; Wang Y; Dai LZ; Pan L; Gomberg-Maitland M; Jing ZC Heart; 2011 Nov; 97(22):1876-81. PubMed ID: 21948962 [TBL] [Abstract][Full Text] [Related]
37. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Garg N; Sharma MK; Sinha N Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417 [TBL] [Abstract][Full Text] [Related]
38. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results]. Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792 [TBL] [Abstract][Full Text] [Related]
39. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. Aubin MC; Laurendeau S; Mommerot A; Lamarche Y; Denault A; Carrier M; Perrault LP J Cardiovasc Pharmacol; 2008 Jan; 51(1):11-7. PubMed ID: 18209563 [TBL] [Abstract][Full Text] [Related]
40. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]